Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety, Immunogenicity and Compatibility With DTP of a Typhoid Fever Vaccine in Infants

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) )
ClinicalTrials.gov Identifier:
NCT00342628
First received: June 19, 2006
Last updated: May 22, 2012
Last verified: May 2012

June 19, 2006
May 22, 2012
July 2006
April 2008   (final data collection date for primary outcome measure)
Number of Infants With Adverse Reactions After Vaccination [ Time Frame: at 2, 4, 6 and 12 months ] [ Designated as safety issue: Yes ]
Number of infants with Fever>=38.0 C, Induration>=2.5cm at DTP site, Induration>=2.5cm,Vi-rEPA/Hib-TT site, Erythema>=2.5cm, at DTP site, Erythema>=2.5cm, Vi-rEPA/Hib-TT site, Inconsolable crying<4hr, Inconsolable crying>=4hr per injection with Vi conjugate vaccine given in conjunction with DTP in infants.
Routine typhoid vaccine administered along with DTP.
Complete list of historical versions of study NCT00342628 on ClinicalTrials.gov Archive Site
  • IgG Anti-Vi Levels [ Time Frame: cord sera, infants' sera at 7, 12 and 13 months ] [ Designated as safety issue: No ]
    IgG anti-Vi was measured by ELISA and expressed as ELISA units (EU)in all sera.
  • Antibody Responses to Tetanus Toxoid, Diphtheria Toxoid, and Pertussis Toxin [ Time Frame: Cord sera, and infants' sera at 7, 12 and 13 months of age ] [ Designated as safety issue: No ]
    IgG anti-diphtheria toxoid (DT), -tetanus toxoid (TT) and -pertussis toxin (PT) were measured by ELISA in sera of 30 randomly chosen infants per group.
  • Antibody Responses to Hib CP [ Time Frame: Cord sera and infant sera at 7, 12, and 13 months ] [ Designated as safety issue: No ]
    IgG anti-Hib CP was measured by ELISA in sera of 30 randomly chosen infants per group
Not Provided
Not Provided
Not Provided
 
Safety, Immunogenicity and Compatibility With DTP of a Typhoid Fever Vaccine in Infants
Evaluation of the Safety, Immunogenicity and Compatibility With DTP of an Investigational Vi-rEPA Conjugate Vaccine for Typhoid Fever When Administered to Infants in Vietnam Concurrently With DTP

The purpose of this study is to evaluate the safety, immunogenicity, and compatibility of our Vi-rEPA conjugate administered to infants with their routine vaccinations.

We propose to recruit 300 full term healthy newborns in Vietnam and randomly divide them to receive Vi-rEPA plus DTP, Hib-TT (not yet used in Vietnam) plus DTP, or DTP alone. Consent is obtained following interviews of mothers during prenatal visits, or after delivery. All vaccines will be administered at 2, 4, and 6 months. A booster of Vi-rEPA or Hib-TT conjugate will be administered at 12 months of age and reactions monitored at 6, 24 and 48 hours after each injection. Maternal and cord blood samples are collected during labor and at delivery. Blood will be taken at 7, and 12 months of age from all study infants and at 13 months from infants injected with Vi-rEPA or with Hib-TT at 12 months. The blood samples will be assayed for Vi, Hib, diphtheria, tetanus and pertussis antibodies.

The levels of serum IgG anti-Vi elicited by Vi-rEPA administered to infants by the above schedule will be compared to those elicited by this vaccine in 2 to 5 year-olds in the efficacy trial conducted in Dong Thap Province, Vietnam.

Typhoid fever remains common, serious, and difficult-to-treat throughout the world including Vietnam. Limitations of the three licensed typhoid vaccines have prevented their use for routine vaccination of infants. The most recent, Vi polysaccharide typhoid vaccine is useful only in individuals greater than or equal to 5 years of age because of its age-related and T-cell independent properties. The immunogenicity of Vi in individuals less than 5 years-old has been improved by binding it to a protein. In 2 to 4-year-olds, 2 injections of the Vi conjugate induced higher levels of serum IgG anti-Vi than Vi in 5 to 14-year-olds.

A double-blind, placebo controlled and randomized efficacy study in 2 -to-5 years old children in Vietnam showed an over-all efficacy after 27 months of active surveillance followed by 19 months of passive surveillance of 89%. Subsequently a dosage study in the same age group showed the highest antibody levels were induced by the 25 mcg dose.

Now we wish to evaluate the safety, immunogenicity, and compatibility of our Vi-rEPA conjugate administered to infants with their routine vaccinations.

We propose to recruit 300 full term healthy newborns in Vietnam and randomly divide them to receive Vi-rEPA plus DTP (Group A), Hib-TT (not yet used in Vietnam) plus DTP (Group B), or DTP alone (Group C). Maternal and cord blood are taken routinely on all deliveries in Vietnam; these sera will be retrieved for storage when consent is obtained following interviews of mothers during prenatal visits, or after delivery. All vaccines will be administered at 2, 4, and 6 months. A booster of Vi-rEPA or Hib-TT conjugate will be administered at 12 months of age and reactions monitored at 6, 24 and 48 hours after each injection. Blood will be taken at 7, and 12 months of age from all study infants and at 13 months from infants injected with Vi-rEPA or with Hib-TT at 12 months. The blood samples will be assayed for Vi, Hib, diphtheria, tetanus and pertussis antibodies.

The levels of serum IgG anti-Vi elicited by Vi-rEPA administered to infants by the above schedule will be compared to those elicited by this vaccine in 2 to 5 year-olds in the efficacy trial conducted in Dong Thap.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Typhoid Fever
  • Biological: Vi-rEPA conjugate vaccine for typhoid fever
    Vi-rEPA contains a 25 ug/dose of Vi (Sanofi-Pasteur Lot 130) and rEPA in 0.2 N NaCl, 10 mM phosphate PH 7.2 and 0.01% thimerosal.
    Other Name: Vi conjugate
  • Biological: Hib-TT
    Hib-TT is Hemophilus influenzae type b-tetanus toxoid conjugate vaccine (ActHib, NDC#49281-545-05 Sanofi-Pasteur, France) in single-dose vials containing 10 ugof Hib CP conjugated to 24 ug of tetanus toxoid
    Other Name: Hib conjugate
  • Biological: DTP
    DTP, diphtheria, tetanus toxoid and pertussis vaccine were from the Ministry of Health, Vietnam for routine infant immunization
    Other Name: EPI vaccine
  • Experimental: Vi-rEPA plus DTP
    Vi-rEPA and DTP at 2, 4, 6 months, and Vi-rEPA at 12 months
    Interventions:
    • Biological: Vi-rEPA conjugate vaccine for typhoid fever
    • Biological: DTP
  • Active Comparator: Hib-TT plus DTP
    Hib-TT and DTP at 2,4 and 6 months, Hib-TT at 12 months
    Interventions:
    • Biological: Hib-TT
    • Biological: DTP
  • Active Comparator: EPI
    DTP at 2,4 and 6 months
    Intervention: Biological: DTP

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
301
January 2011
April 2008   (final data collection date for primary outcome measure)

Inclusion criteria:

  • Healthy full-term newborns.
  • Birth weights of >=2500 grams.

Exclusion criteria:

  • Newborns without maternal and cord blood samples
  • Newborns born to mothers with serious medical problems.
Both
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
Vietnam
 
NCT00342628
999999050, OH99-CH-N050
Yes
National Institutes of Health Clinical Center (CC) ( Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) )
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Not Provided
Study Director: Feng-Ying (Kimi) Lin, MD, MPH PDMI, NICHD, NIH
National Institutes of Health Clinical Center (CC)
May 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP